Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Dropbox Inc (DBX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Dropbox Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.7 (market cap $29.60B), while Dropbox Inc trades at $33.56 (market cap $7.41B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4× Dropbox Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DBX | |
|---|---|---|
Market Cap | $29.60B | $7.41B |
Sector | Health | Technology |
52-Week High | $491.22 | $35.00 |
52-Week Low | $205.48 | $22.06 |
Enterprise Value | $27.56B | $10.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Dropbox (DBX) trades at $33.68, down 2.63% on the day, yet maintains a bullish technical trend with consistent earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.75, exceeding expectations of $0.74, driven by core file-sync-and-share growth and AI expansion. Despite a negative shareholder equity position, operating cash flow remains strong at $952 million for 2025, supporting ongoing business investments.
The outlook is cautiously optimistic, with raised 2026 guidance signaling management confidence, but high debt levels and competitive pressures in cloud storage pose risks. Analyst sentiment is mixed, with 37.5% recommending buy, highlighting potential upside if execution continues, though investors should weigh valuation against balance sheet concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
